Actinium Pharmaceuticals, Inc.-Orlando Lunch 3/11/2025

**Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration.**

Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Tuesday, March 11, 2025

LUNCH

Eddie V's Prime Seafood

7488 W. Sand Lake Road

Orlando, FL 32819

Promptly at 12:00 PM

Join Actinium Pharmaceuticals, Inc. for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience.

We hope you can join our presentation

About Actinium Pharmaceuticals, Inc.

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

VIDEO

Actinium-225 Spotlight: Nurturing Targeted Alpha Therapy from Production to Patient Care and Beyond

In The News

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

12:00 p.m. to 1:30 p.m. – Presentation and Lunch

Contact:

Raymond Oliver

CEO, Bear Creek Capital

321-439-2120

bearcreekcapital06@gmail.com